An AI tool using temporal learning significantly outperforms traditional methods in predicting pediatric glioma recurrence, achieving 75% to 89% accuracy. The AI model analyzes multiple brain scans ...

Treatment for glioma has long relied on MRI imaging to track tumor markers and treatment response. But new findings suggest a new method could provide additional data about tumor markers before ...

Researchers trained and validated a deep learning model that can detect subtle changes across post-treatment brain scans and forecast glioma recurrence with up to 89 percent accuracy. Artificial ...

These tumors are less likely to spread to surrounding tissues than higher-grade tumors, so they often have better outcomes. In the past, pediatric gliomas were classified into low-grade and high-grade ...

Pediatric high-grade gliomas, particularly H3K27M diffuse midline gliomas (DMG), are aggressive malignant brain tumors with a poor prognosis. Previous research suggests that platelet-derived growth ...

Please provide your email address to receive an email when new articles are posted on . Two-thirds of patients with relapsed pediatric low-grade glioma treated with tovorafenib responded to therapy, ...

Pixclara, a glioma-imaging agent, has been granted priority review by the FDA with a decision deadline of April 26, 2025. The agent targets LAT and LAT2 proteins, aiding in distinguishing glioma ...

MedPage Today brought together three expert leaders for a virtual roundtable discussion on pediatric low-grade glioma. Moderator Jason Fangusaro, MD, of Emory University School of Medicine in Atlanta, ...

A three-dimensional experimental system has been developed to study the response to drugs in low-grade glioma, a tumor of the central nervous system that often occurs in children. The project, ...

Plus Therapeutics Inc. (NASDAQ:PSTV) said the U.S. Food and Drug Administration has granted Orphan Drug Designation to REYOBIQ (rhenium Re186 obisbemeda) for the treatment of pediatric malignant ...